image
Healthcare - Medical - Devices - NYSE - US
$ 72.24
1.88 %
$ 42.3 B
Market Cap
30.87
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one EW stock under the worst case scenario is HIDDEN Compared to the current market price of 72.2 USD, Edwards Lifesciences Corporation is HIDDEN

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one EW stock under the base case scenario is HIDDEN Compared to the current market price of 72.2 USD, Edwards Lifesciences Corporation is HIDDEN

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one EW stock under the best case scenario is HIDDEN Compared to the current market price of 72.2 USD, Edwards Lifesciences Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EW

image
$78.0$78.0$76.0$76.0$74.0$74.0$72.0$72.0$70.0$70.0$68.0$68.0$66.0$66.0$64.0$64.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 Mar
FINANCIALS
5.44 B REVENUE
-9.41%
1.38 B OPERATING INCOME
-10.13%
4.17 B NET INCOME
197.33%
542 M OPERATING CASH FLOW
-39.46%
2.31 B INVESTING CASH FLOW
1230.78%
-983 M FINANCING CASH FLOW
-38.26%
1.39 B REVENUE
2.32%
313 M OPERATING INCOME
-20.72%
346 M NET INCOME
-88.72%
-128 M OPERATING CASH FLOW
-36.24%
-577 M INVESTING CASH FLOW
-21.35%
28.6 M FINANCING CASH FLOW
102.93%
Balance Sheet Edwards Lifesciences Corporation
image
Current Assets 6.29 B
Cash & Short-Term Investments 3.98 B
Receivables 727 M
Other Current Assets 1.58 B
Non-Current Assets 6.77 B
Long-Term Investments 308 M
PP&E 1.78 B
Other Non-Current Assets 4.68 B
30.45 %5.57 %12.12 %13.67 %35.83 %Total Assets$13.1b
Current Liabilities 1.51 B
Accounts Payable 197 M
Short-Term Debt 46.8 M
Other Current Liabilities 1.26 B
Non-Current Liabilities 1.49 B
Long-Term Debt 677 M
Other Non-Current Liabilities 811 M
6.60 %42.14 %22.61 %27.09 %Total Liabilities$3.0b
EFFICIENCY
Earnings Waterfall Edwards Lifesciences Corporation
image
Revenue 5.44 B
Cost Of Revenue 1.12 B
Gross Profit 4.32 B
Operating Expenses 2.94 B
Operating Income 1.38 B
Other Expenses -2.79 B
Net Income 4.17 B
6b6b5b5b4b4b3b3b2b2b1b1b005b(1b)4b(3b)1b3b4bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
79.46% GROSS MARGIN
79.46%
25.35% OPERATING MARGIN
25.35%
76.75% NET MARGIN
76.75%
41.75% ROE
41.75%
31.98% ROA
31.98%
10.72% ROIC
10.72%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Edwards Lifesciences Corporation
image
2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 4.17 B
Depreciation & Amortization 155 M
Capital Expenditures -252 M
Stock-Based Compensation 162 M
Change in Working Capital -259 M
Others -3.58 B
Free Cash Flow 290 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Edwards Lifesciences Corporation
image
Wall Street analysts predict an average 1-year price target for EW of $81.6 , with forecasts ranging from a low of $66 to a high of $110 .
EW Lowest Price Target Wall Street Target
66 USD -8.64%
EW Average Price Target Wall Street Target
81.6 USD 12.92%
EW Highest Price Target Wall Street Target
110 USD 52.27%
Price
Max Price Target
Min Price Target
Average Price Target
11011010010090908080707060605050May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Edwards Lifesciences Corporation
image
Sold
0-3 MONTHS
4.53 M USD 6
3-6 MONTHS
3.84 M USD 6
6-9 MONTHS
1.27 M USD 3
9-12 MONTHS
13 M USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
49.8 K USD 1
9-12 MONTHS
7. News
Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW's shares remain undervalued with a reduced P/E multiple of 33x, yielding a price target of $84. Key risks include slower TAVR growth in Japan and hospital demand uncertainties, but long-term sales growth targets remain optimistic. seekingalpha.com - 1 week ago
Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor SUNNYVALE, Calif.--(BUSINESS WIRE)--Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operation. businesswire.com - 4 weeks ago
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Life. businesswire.com - 1 month ago
Should Edwards Lifesciences Stock Remain in Your Portfolio Now? EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm. zacks.com - 1 month ago
Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength On Tuesday, Edwards Lifesciences EW reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all product groups. benzinga.com - 1 month ago
EW Stock Up on Q4 Earnings and Revenue Beat, Margins Crash Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart? zacks.com - 1 month ago
Edwards Lifesciences Corporation (EW) Q4 2024 Earnings Call Transcript Edwards Lifesciences Corporation (NYSE:EW ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zovighian - Chief Executive Officer Scott Ullem - Corporate Vice President and Chief Financial Officer Daveen Chopra - Corporate Vice President, TMTT Larry Wood - Corporate Vice President and Group President of TAVR and SSH Conference Call Participants David Roman - Goldman Sachs Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Travis Steed - Bank of America Vijay Kumar - Evercore ISI Frederick Wise - Stifel Matthew Miksic - Barclays Matthew Taylor - Jefferies Joanne Wuensch - Citibank Mark Wilterding [Starts Abruptly] included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections. seekingalpha.com - 1 month ago
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 month ago
Edwards Lifesciences beats profit estimate on strength in heart devices Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices. reuters.com - 1 month ago
Edwards Lifesciences Reports Fourth Quarter Results IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.581; adjusted2 EPS of $0.59, driven by strong top-line performance Presen. businesswire.com - 1 month ago
Insights Into Edwards Lifesciences (EW) Q4: Wall Street Projections for Key Metrics Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024. zacks.com - 1 month ago
ITGR or EW: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integer (ITGR) and Edwards Lifesciences (EW). But which of these two stocks is more attractive to value investors? zacks.com - 1 month ago
8. Profile Summary

Edwards Lifesciences Corporation EW

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 42.3 B
Dividend Yield 0.00%
Description Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Contact One Edwards Way, Irvine, CA, 92614 https://www.edwards.com
IPO Date March 27, 2000
Employees 15800
Officers Mr. Mark Wilterding Vice President of Investor Relations Mr. Arnold A. Pinkston J.D. Corporate Vice President & General Counsel Mr. Donald E. Bobo Jr. Corporate Vice President of Strategy & Corporate Development Ms. Christine Z. McCauley Corporate Vice President of Human Resources Mr. Andrew M. Dahl Principal Accounting Officer, Senior Vice President & Corporate Controller Mr. Scott B. Ullem Corporate Vice President & Chief Financial Officer Mr. Dirksen J. Lehman Corporate Vice President of Public Affairs Mr. Bernard J. Zovighian Chief Executive Officer & Director Mr. Larry L. Wood Corporate Vice President and Group President of TAVR & Surgical Structural Heart Dr. Todd J. Brinton FACC, M.D. Corporate Vice President of Advanced Technology & Chief Scientific Officer